Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ROBAXISAL vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is not fully understood, but it is believed to involve general central nervous system depression and inhibition of polysynaptic reflexes in the spinal cord. Aspirin inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and anti-inflammatory effects, and also irreversibly inhibits platelet aggregation.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: Chronic low back pain, fibromyalgia, tension headache, nocturnal leg cramps
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
Oral: 2 tablets (methocarbamol 750 mg / aspirin 650 mg) 4 times daily.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Methocarbamol: 1.0–2.0 hours (prolonged in renal impairment); guaifenesin: approximately 1 hour.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Methocarbamol is metabolized primarily via dealkylation and glucuronidation; unknown cytochrome P450 involvement. Aspirin is hydrolyzed to salicylic acid, which is then conjugated with glycine (forming salicyluric acid) and glucuronic acid, and undergoes oxidative metabolism via CYP2C9 (minor pathway).
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Methocarbamol: renal (primarily as glucuronide and sulfate conjugates, with <2% unchanged); guaifenesin: renal (metabolites, <1% unchanged). No significant biliary/fecal elimination.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Methocarbamol: 46–50% (primarily to albumin); guaifenesin: negligible.
Approximately 90–95% bound, primarily to albumin.
Methocarbamol: 0.6–0.8 L/kg; guaifenesin: not well characterized (likely <1 L/kg).
0.46–0.64 L/kg; indicates distribution into total body water.
Methocarbamol: ~100% oral (well absorbed, but extensive first-pass metabolism); guaifenesin: ~80–90% oral (undergoes first-pass metabolism).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Contraindicated if GFR <30 m L/min due to aspirin component. For GFR 30-60 m L/min, reduce dose to 1 tablet 4 times daily; avoid if possible.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Child-Pugh A: No adjustment needed. Child-Pugh B or C: Avoid use due to aspirin component (risk of bleeding) and methocarbamol metabolism concerns.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Not recommended for use in children and adolescents due to risk of Reye's syndrome from aspirin.
Not established; safety and efficacy not studied in pediatric patients.
Avoid use in elderly due to increased risk of gastrointestinal bleeding, renal impairment, and drug interactions; consider alternative therapy.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
No FDA black box warning is present for ROBAXISAL.
None
Risk of Reye syndrome with aspirin use in children or teenagers with viral illnesses,Methocarbamol may cause CNS depression (drowsiness, dizziness) and impair mental or physical abilities,Aspirin increases risk of bleeding, including gastrointestinal bleeding and intracranial hemorrhage,Methocarbamol may cause seizures in patients with known seizure disorders,Cross-allergenicity with aspirin in patients with NSAID hypersensitivity
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to methocarbamol or aspirin,History of aspirin-induced asthma or NSAID-induced urticaria,Active peptic ulcer disease or gastrointestinal bleeding,Hemophilia or other bleeding disorders,Severe renal impairment (e GFR <30 m L/min),Severe hepatic impairment,Children and teenagers with viral infections due to risk of Reye syndrome,Concurrent use of methotrexate (high dose) or anticoagulants
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Avoid alcohol and caffeine-containing beverages. Take with food to minimize GI irritation. Do not take with other NSAIDs, aspirin, or anticoagulants. Avoid high-fat meals, which may delay absorption of aspirin.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
First trimester: No well-controlled studies; animal data suggest risk of skeletal anomalies at high doses; avoid unless benefit outweighs risk. Second/third trimester: No known teratogenicity; preterm labor risk with high doses due to skeletal muscle relaxation.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Limited data; methocarbamol and aspirin (in Robaxisal) are excreted in breast milk; M/P ratio not established for methocarbamol; aspirin may cause Reye's syndrome in infants; avoid breastfeeding.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No standard dose adjustment; use lowest effective dose for shortest duration. Increased renal clearance in pregnancy may reduce methocarbamol levels, but safety data insufficient for routine dose increase.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
ROBAXISAL combines methocarbamol, a centrally acting muscle relaxant, with aspirin, an NSAID. Monitor for GI bleeding, especially in elderly or those on anticoagulants. Avoid in patients with peptic ulcer disease or aspirin allergy. Methocarbamol may cause sedation and impair motor skills; caution with driving or operating machinery. Onset of methocarbamol's muscle relaxant effect is within 30 minutes; aspirin absorption is rapid. Not recommended for use beyond 2-3 weeks due to lack of long-term efficacy data.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take with food or a full glass of water to reduce stomach upset.,Do not crush or chew the tablets; swallow whole.,Avoid alcohol, as it increases sedation and GI irritation risk.,Do not use other aspirin-containing or NSAID products while taking this medication.,Report signs of bleeding (black stools, vomit with coffee-ground appearance) or allergic reactions (rash, swelling, difficulty breathing) immediately.,This medication may cause drowsiness or dizziness; avoid driving or hazardous activities until you know how it affects you.,Do not use for more than 2-3 weeks unless directed by your doctor.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ROBAXISAL vs CHLORZOXAZONE, answered by our medical review team.
ROBAXISAL is a Skeletal Muscle Relaxant that works by Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is not fully understood, but it is believed to involve general central nervous system depression and inhibition of polysynaptic reflexes in the spinal cord. Aspirin inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and anti-inflammatory effects, and also irreversibly inhibits platelet aggregation.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ROBAXISAL and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ROBAXISAL is: Oral: 2 tablets (methocarbamol 750 mg / aspirin 650 mg) 4 times daily.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ROBAXISAL and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ROBAXISAL is classified as Category C. First trimester: No well-controlled studies; animal data suggest risk of skeletal anomalies at high doses; avoid unless benefit outweighs risk. Second/third trimester: No known ter. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.